Mesoblast takes US cancer giant Celgene as latest partner

Original article by Jessica Gardner
The Australian Financial Review – Page: 17 : 14-Apr-15

Shares in Mesoblast rose by 24 per cent to $A3.99 on 13 April 2015, after US-based Celgene acquired a stake of around 4.5 per cent in the listed biotechnology group. Celgene paid $A58.5m for 15.3 million shares in Mesoblast, which specialises in the development of stem cell treatments for a range of medical conditions. Celgene will also have first right of refusal to license some of Mesoblast’s products

CORPORATES
MESOBLAST LIMITED – ASX MSB, CELGENE INCORPORATED, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, LODGE PARTNERS PTY LTD

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s